ASTROCYTOMA

This early-phase study tests a new treatment for people with recurrent high-grade brain tumors (astrocytomas). A specially designed virus carrying two 'suicide' genes is injected into the tumor cavity during surgery, followed by targeted radiation. The main goal is to find the sa…

This early-phase study tests a new drug called FT536 for adults with a fast-growing brain tumor (WHO grade 4 astrocytoma) that has come back after standard treatment. The drug is injected directly into the tumor during surgery. The main goal is to check safety and find the right …

This study follows children who previously took dabrafenib and/or trametinib for certain brain tumors. It aims to see how safe these drugs are over the long term by tracking side effects and monitoring growth. About 163 children are enrolled, and the study is no longer recruiting…

This study tests a combination of two drugs—ATRA and retifanlimab—in people with a specific type of brain tumor (IDH-mutant glioma) that has returned after prior treatment. The goal is to see if this combo can shrink tumors or slow their growth by boosting the body's immune respo…

This early-stage trial tests a specially engineered virus, G207, in children and young adults whose cerebellar brain tumors have come back or not responded to standard treatments. The virus is injected directly into the tumor, and a single low dose of radiation is given to help t…

This study tests a shorter, more intense radiation schedule for people whose glioblastoma (a severe brain cancer) has returned after standard treatment. About 28 adults will receive radiation 4 times a week for 1 to 3 weeks. The goal is to find the safest dose that controls the t…

This study tests a drug called tuvusertib in people whose IDH-mutant astrocytoma (a type of brain tumor) has returned after initial treatment. The drug targets a specific genetic change (ATRX mutation) to try to stop the tumor from growing. About 56 adults will take part, and the…

This study tests whether the blood thinner apixaban can safely prevent blood clots in people with newly diagnosed grade 4 glioma (a type of brain cancer). About 40 participants will take apixaban while receiving standard radiation and chemotherapy. The main goal is to check for b…

This study is testing whether a program called FearLess is practical and well-received by people with primary malignant brain tumors and their caregivers. The goal is to see if the recruitment methods, study design, and program itself work well before a larger trial. About 112 pa…